Skip to main content

UCB Value Stock - Dividend - Research Selection

UCB SA

ISIN: BE0003739530, WKN: 852738

Market price date: 21.01.2022
Market price: 91,14 EUR


UCB SA Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 27-09-2021
Cash flow
Net operating cash flow 1.081.000.000
Capital Expenditures -256.000.000
Free cash flow 825.000.000
Balance sheet
Total Equity 7.271.000.000
Liabilities & Shareholders equity 13.319.000.000
Income statement
Net income 732.000.000
Eps (diluted) 3,770
Diluted shares outstanding 194.250.000
Net sales/revenue 5.347.000.000

Fundamental ratios calculated on: 21-01-2022

Ratios
Key figures 21-01-2022
Cash flow
P/C 16,38
   
P/FC 21,46
Balance sheet
ROI5,50
ROE54,59
Income statement
P/E24,18
Div. Yield0,98%
P/B2,44
P/S3,31


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolUCB.BR
Market Capitalization21.472.339.968,00 USD
CountryBelgium
IndicesSTOXX EUROPE 600,MSCI World Index
SectorsBiotechnology
Raw Data SourceIFRS in Millionen EUR
Stock Split1999-01-04,100.000000/1.000000
Internetwww.ucb.com


Description of the company

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.ucb.com


NEWS